{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T01:39:43Z","timestamp":1776908383621,"version":"3.51.2"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplant Immunology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.trim.2023.101808","type":"journal-article","created":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T19:29:27Z","timestamp":1677266967000},"page":"101808","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Post-transplant cyclophosphamide and early mixed donor Chimerism in myeloid malignancies; a single-center experience"],"prefix":"10.1016","volume":"77","author":[{"given":"Fieke W.","family":"Hoff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen S.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prapti A.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naveen","family":"Premnath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jude","family":"Khatib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirjana","family":"Tadic-Ovcina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abeer","family":"AhmedRabie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debra","family":"Helton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selamawit","family":"Yohannes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaime","family":"Shahan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hetalkumari","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Praveen Ramakrishnan","family":"Geethakumari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madhuri","family":"Vusirikala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert H.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yazan F.","family":"Madanat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.trim.2023.101808_bb0005","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s41409-019-0615-0","article-title":"Post-transplantation cyclophosphamide for chimerism-based tolerance","volume":"54","author":"McCurdy","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.trim.2023.101808_bb0010","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1053\/j.seminoncol.2012.09.005","article-title":"Post-transplantation cyclophosphamide for tolerance induction in HLA-Haploidentical bone marrow transplantation","volume":"39","author":"Luznik","year":"2012","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.trim.2023.101808_bb0015","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1200\/JCO.2013.54.0625","article-title":"Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using Myeloablative Busulfan and Fludarabine conditioning","volume":"32","author":"Kanakry","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trim.2023.101808_bb0020","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1182\/blood-2015-10-672071","article-title":"Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation","volume":"127","author":"Mielcarek","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.trim.2023.101808_bb0025","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1182\/blood.V98.12.3456","article-title":"Durable engraftment of major histocompatibility complex\u2013incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide","volume":"98","author":"Luznik","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.trim.2023.101808_bb0030","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/imj.13522","article-title":"Acute myeloid leukaemia relapsing after allogeneic haemopoietic stem cell transplantation: prognostic factors and impact of initial therapy of relapse","volume":"48","author":"Lim","year":"2018","journal-title":"Intern. Med. J."},{"key":"10.1016\/j.trim.2023.101808_bb0035","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/s41409-020-01163-z","article-title":"Relapse of acute myeloid leukemia after allogeneic hematopoietic cell transplantation: clinical features and outcomes","volume":"56","author":"Yanada","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.trim.2023.101808_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100673","article-title":"Is microchimerism a sign of imminent disease recurrence after allogeneic hematopoietic stem cell transplantation? A systematic review of the literature","volume":"44","author":"Haugaard","year":"2020","journal-title":"Blood Rev."},{"key":"10.1016\/j.trim.2023.101808_bb0045","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.trim.2023.101808_bb0050","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trim.2023.101808_bb0055","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1182\/blood-2013-10-525873","article-title":"Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice","volume":"124","author":"Ganguly","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.trim.2023.101808_bb0060","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-Haploidentical bone marrow transplantation for hematologic malignancies using Nonmyeloablative conditioning and high-dose, Posttransplantation Cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.trim.2023.101808_bb0065","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1182\/bloodadvances.2016002766","article-title":"Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide","volume":"1","author":"Kasamon","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.trim.2023.101808_bb0070","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/172603a0","article-title":"\u2018Actively acquired Tolerance\u2019 of foreign cells","volume":"172","author":"Billingham","year":"1953","journal-title":"Nature"},{"key":"10.1016\/j.trim.2023.101808_bb0075","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1126\/science.133.3449.307","article-title":"Immunological recognition of self","volume":"133","author":"Burnet","year":"1961","journal-title":"Science"},{"key":"10.1016\/j.trim.2023.101808_bb0080","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1016\/j.bbmt.2019.07.028","article-title":"Haploidentical transplantation with post-transplant cyclophosphamide versus unrelated donor hematopoietic stem cell transplantation: a systematic review and Meta-analysis","volume":"25","author":"Arcuri","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.trim.2023.101808_bb0085","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1053\/bbmt.2001.v7.pm11669214","volume":"7","author":"Antin","year":"2001","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.trim.2023.101808_bb0090","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.bbmt.2014.05.025","article-title":"Donor Chimerism early after reduced-intensity conditioning hematopoietic stem cell transplantation predicts relapse and survival","volume":"20","author":"Koreth","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.trim.2023.101808_bb0095","doi-asserted-by":"crossref","first-page":"e26493","DOI":"10.1002\/pbc.26493","article-title":"Early mixed T-cell chimerism is predictive of pediatric AML or MDS relapse after hematopoietic stem cell transplant","volume":"64","author":"Broglie","year":"2017","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.trim.2023.101808_bb0100","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.exphem.2010.08.006","article-title":"Chimerism studies with quantitative real-time PCR in stem cell recipients with acute myeloid leukemia","volume":"38","author":"Wiedemann","year":"2010","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.trim.2023.101808_bb0105","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1365-2141.2005.05372.x","article-title":"Impact of chimaerism analysis and kinetics on allogeneic haematopoietic stem cell transplantation outcome after conventional and reduced-intensity conditioning regimens","volume":"128","author":"Michallet","year":"2005","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.trim.2023.101808_bb0110","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1016\/j.bbmt.2014.07.003","article-title":"Early donor Chimerism levels predict relapse and survival after allogeneic stem cell transplantation with reduced-intensity conditioning","volume":"20","author":"Reshef","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.trim.2023.101808_bb0115","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41409-022-01579-9","article-title":"Chimerism analysis for clinicians: a review of the literature and worldwide practices","volume":"57","author":"Blouin","year":"2022","journal-title":"Bone Marrow Transplant."}],"container-title":["Transplant Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327423000254?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327423000254?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T18:03:28Z","timestamp":1760810608000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0966327423000254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":23,"alternative-id":["S0966327423000254"],"URL":"https:\/\/doi.org\/10.1016\/j.trim.2023.101808","relation":{},"ISSN":["0966-3274"],"issn-type":[{"value":"0966-3274","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Post-transplant cyclophosphamide and early mixed donor Chimerism in myeloid malignancies; a single-center experience","name":"articletitle","label":"Article Title"},{"value":"Transplant Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trim.2023.101808","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101808"}}